Bristol-Myers Squibb and AstraZeneca Settle Anti-PD-L1 Antibody Product Litigation | Goodwin
We previously reported on Bristol-Myers Squibb’s (“BMS”) complaint alleging AstraZeneca’s PD-L1 antibody product, IMFINZI (durvalumab), infringed U.S. Patent No. 9,402,899 (“the ’899 patent”). BMS alleged that the ’899 patent covers “Nobel Prize winning methods of treating cancer” by using “an antibody to inhibit the interaction between PD-1 and PD-L1 to treat cancer in patients.” On July 28, 2023, BMS and AstraZeneca filed a Joint Stipulation of Dismissal with Prejudice indicating that the parties have agreed to settle the litigation and dismiss the action with prejudice. On July 31, 2023, the district court judge ordered the dismissal.
[View source.]
